NCT06931990View on ClinicalTrials.gov

A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

October 30, 2025

Study Completion Date

December 30, 2025

Conditions
Atopic Dermatitis (AD)
Interventions
DRUG

LT-002-158 tablets

The subjects will orally administered LT-002-158 tablets once a day.

Sponsors
All Listed Sponsors
lead

Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.

INDUSTRY